Skip to main content

Formulate

Find pharma jobs. Prep for interviews like no one else can.

Browse

Jobs Companies Drugs Indications Career Advisor About

Insider Intel

Intelligence Hub Therapeutic Areas Contribute Intro Network Salary Explorer For Employers

Legal

Privacy Policy Terms of Service About Our Crawler Content Removal Your Privacy Choices

© 2026 Formulate. Pharma Jobs with Drug Intelligence.

argenx Jobs | Formulate

Jobs
argenx

argenx Jobs

Belgium - Zwijnaarde

Biotechnology

argenx is a life sciences company focused on Antibody therapies.

45 open positions at argenx

View Full Profile

Filters:Immunology ×

Director, Employee Communications & Engagement – Global Commercialization

argenx

Posted 4d ago

Boston, MA, USA

Full-time

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

CommunicationsImmunologyExecutive

H-1B · 1 FY23

Project Manager Preclinical Product Development

argenx

Posted 4d ago

Gent, Belgium

Full-time

Medical Science Liaison (Northwest)

argenx

Posted 1w ago

United States - Field; Seattle; Portland, OR

$184K - $253K

Full-time

Key Account Manager, Brazil (São Paolo)

argenx

Posted 1w ago

Brazil - Field

Full-time

Key Account Manager, Brazil (Cruitiba)

argenx

Posted 1w ago

Brazil - Field

Full-time

Key Account Manager, Brazil (Recife)

argenx

Posted 1w ago

Brazil - Field

Full-time

DT Business Lead - Research

argenx

Posted 1w ago

Gent, Belgium

Full-time

DT Strategic Partnerships Lead

argenx

Posted 1w ago

Remote

Full-time

Device Expert Director, Technical Operations

argenx

Posted 2w ago

Remote

$188K - $259K

Full-time

Digital Technology Product Owner, US HCP Experience

argenx

Posted 2w ago

Boston, MA, USA

$184K - $253K

Full-time

Digital Technology Product Owner, US Market Access

argenx

Posted 2w ago

Boston, MA, USA

$156K - $215K

Full-time

Territory Business Manager, Green Bay Wisconsin

argenx

Posted 2w ago

Green Bay

$140K - $193K

Full-time

Medical Science Liaison, Multi-Specialty (Northeast or Southeast)

argenx

Posted 2w ago

United States - Field

$184K - $253K

Full-time

Medical Science Liaison, Multi-Specialty

argenx

Posted 2w ago

Minneapolis; St Louis

$184K - $253K

Full-time

Medical Science Liaison, Multi-Specialty (Central)

argenx

Posted 2w ago

United States - Field

$184K - $253K

Full-time

Medical Science Liaison - Houston and Austin

argenx

Posted 2w ago

Houston

$184K - $253K

Full-time

Senior Scientist DP Commercial

argenx

Posted 2w ago

Gent, Belgium

Full-time

Associate Director, US Commercial Insights - Rheumatology

argenx

Posted 3w ago

Remote

$168K - $231K

Full-time

Regional Pharmacovigilance Lead (US)

argenx

Posted 3w ago

United States

$192K - $264K

Full-time

Executive Assistant

argenx

Posted 3w ago

Boston, MA, USA

$76K - $105K

Full-time

1
2
3
Next

Company Overview

Active Jobs

48

Pipeline Programs

86

Drug Products

2

Clinical Trials

89

View Full Company Profile

Therapeutic Areas

Neurology Immunology Oncology

Links

Company Website Careers Page

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

Research & DevelopmentImmunologyMANAGER

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

Medical AffairsImmunologyMID

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

CommercialImmunologyMANAGER

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

CommercialImmunologyMANAGER

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

CommercialImmunologyMANAGER

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

Research & DevelopmentImmunologySenior

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

RemoteBusiness DevelopmentImmunologySenior

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

RemoteImmunologyExecutive

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

ImmunologyMID

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

CommercialImmunologyMID

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

CommercialImmunologyMANAGER

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

Medical AffairsImmunologyMID

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

Medical AffairsImmunologyMID

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

Medical AffairsImmunologyMID

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

Medical AffairsImmunologyMID

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

Research & DevelopmentImmunologySenior

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

RemoteCommercialImmunologyExecutive

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

PharmacovigilanceImmunologySenior

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

ImmunologyExecutive

H-1B · 1 FY23